Professor Jiang Zefei: Waving goodbye to the old years, striding to welcome the new dynasty, breast cancer diagnosis and treatment extended to diversification Review of the annual progress of breast cancer treatment in 2022

On January 7, 2023, the "2022 Annual Progress Review of Breast Cancer Treatment", a grand event in the field of breast cancer, opened
in Beijing.
The conference reviewed the important academic progress of breast cancer in 2022, and launched the update of the 2023 version of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Diagnosis and Treatment Guidelines
.
Professor Jiang Zefei, Chairman of the Conference, Vice Chairman and Secretary-General of CSCO, was invited to share the highlights of the conference and talk about the new progress
in the diagnosis and treatment of breast cancer.

- Professor Jiang Zefei -

Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO).

Chairman of the Breast Disease Branch of Beijing Medical Association

Chairman-elect of the Breast Cancer Special Committee of the Chinese Anti-Cancer Association (CACA).

Former Chairman of the CSCO Breast Cancer Committee

The "2022 Annual Progress Review of Breast Cancer Treatment" conference reviewed the important progress
in the field of breast cancer at home and abroad in 2022.
What are the significance and highlights of this conference?

Professor Jiang Zefei

In order to better start, the "2022 Annual Progress Review of Breast Cancer Treatment" conference adheres to the past tradition, specially invited Academician Song Erwei, Academician Xu Binghe, Professor Shao Zhimin, Professor Wu Jiong, Professor Liu Yinhua and other well-known experts and scholars in the field of breast cancer in the field of breast cancer, to review the hot issues in the fields of translational research, immunotherapy, surgical treatment, internal medicine treatment and pathology in the past year, integrating international progress and China's contribution, providing new ideas for the precision diagnosis and treatment of breast cancer.
It also points out the direction
for future breast cancer research.

Yimaitong: What are the clinical studies that have a greater impact on the diagnosis and treatment of breast cancer in 2022? What decisions have changed in clinical practice?

Professor Jiang Zefei

Looking back on 2022, we have worked hard and harvested a lot
.
In the field of hormone receptor-positive breast cancer, more and more CDK4/6 inhibitors have come out at home and abroad, changing our clinical practice, and the accessibility of drugs is also continuously improving
.
In the future, with the wide application of CDK4/6 inhibitors, their combination strategies, drug resistance mechanisms, biomarkers and other research directions require further thinking and planning
.
In the field of HER2-positive breast cancer, from single target to double target, from small molecule tyrosine kinase inhibitor (TKI) to antibody drug conjugate (ADC), new anti-HER2 drugs are emerging, and China's original innovative products have also made rapid progress, enriching the drug selection
of preoperative, postoperative and advanced treatment of breast cancer.
In the field of triple-negative breast cancer, the team of Academician Song Erwei and Professor Shao Zhimin have worked hard in translational research, committed to promoting the transformation of clinical results, and constantly exploring more possibilities
of immunotherapy in the treatment of triple-negative breast cancer.
I believe that in the future, with the continuous advancement of clinical research and the continuous popularization of therapeutic drugs, the individualized treatment options for breast cancer will be more diversified, which will help solve more clinical practical problems
.

What will be discussed in the "2023 CSCO BC Diagnosis and Treatment Guidelines Update" session? When is the new guide scheduled for release?

Professor Jiang Zefei

Thank you very much for your interest
in the CSCO BC guidelines.
Based on evidence-based medical evidence and the accessibility of diagnosis and treatment products, the new version of the guidelines is updated
from the perspectives of preoperative neoadjuvant therapy, adjuvant therapy, and treatment and disease management of recurrent metastatic breast cancer.
In this "2023 CSCO BC Diagnosis and Treatment Guidelines Update", we prepared 100 questions based on relevant opinions and suggestions, and invited experts and scholars in the field of breast cancer to vote, including not only well-known experts, but also general doctors and young scholars to participate, so that the guidelines are more grounded and more in line with Chinese clinical practice
.
In addition, the smart version of the guidelines will also be updated to better provide real-time dynamic guidance for clinical trials
.
The paper version of the CSCO BC Diagnosis and Treatment Guidelines is scheduled to be officially promulgated at the annual meeting of the CSCO Breast Cancer Special Committee to be held in Beijing on April 7, 2023, and a series of new version of the guidelines will be organized by the CSCO BC Special Committee in the future to further promote the improvement of the standardized diagnosis and treatment of breast cancer in China
.

Edited by Faline

Reviewer: Professor Jiang Zefei

Typesetting: Faline

Execution: Uni

This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.